When killer lymphocytes recognize cells infected with intracellular pathogens, they release their cytotoxic granule contents to induce apoptosis of the infected target cell. However, what happens to intracellular parasites during this process is unclear. Host cell apoptosis is triggered by cytotoxic granule proteases (granzymes, Gzm), delivered into the target cell by the cholesterol-dependent membrane perturbing protein, perforin (PFN). Cytotoxic granules of humans and some other mammals, but not rodents, contain another pore-forming protein, granulysin (GNLY), which preferentially disrupts cholesterol-poor bacterial, fungal and parasite membranes. We recently found that when human killer lymphocytes recognize bacteria-infected cells, they rapidly kill intracellular bacteria. GNLY delivers Gzms into bacteria where they proteolytically attack bacterial electron transport chain complex I to generate toxic superoxide anion and also proteolytically destroy bacterial oxidative defense enzymes. Preliminary data show that GNLY also delivers Gzms into protozoan parasites (Trypanosoma cruzi, Toxoplasma gondii, Leishmania major), which are rapidly killed, also in a superoxide-dependent manner. Destruction of intracellular parasites relies on the concerted action of all three cytotoxic effector molecules - Gzms, PFN and GNLY. Mice that express a GNLY transgene in killer lymphocytes are able to survive a T. cruzi challenge that is lethal to wild-type (WT) mice. This proposal uses T. cruzi as a model to investigate the hypothesis that GNLY, Gzm and PFN-mediated killing of intracellular protozoan parasites provides strong immune protection against intracellular parasites. We hypothesize that T. cruzi amastigotes are killed before the host cell, which limits the spread of infection. We also hypothesize that killer cells rapidly induce programs of cell death in T. cruzi that share some features with death pathways activated by Gzms in mammalian cells or bacteria. We also hypothesize that direct parasite killing helps control acute infection, enhance vaccine protection and reduce the chagasic pathology of chronic infection. This proposal joins the expertise of two principal investigators, who are leaders in studying (1) how killer cells destroy infected host cels and their pathogens and (2) the immune response to T. cruzi.
The aims of the proposal are to define the features of killer cell-mediated parasite death, identify T. cruzi Gzm substrates that are important in causing death and explore how direct parasite killing contributes to immune defense by comparing infection in WT mice that do not express GNLY with GNLY-transgenic mice.

Public Health Relevance

Chagas disease, caused by chronic infection with the parasite Trypanosoma cruzi, is a neglected public health problem for which there is no good vaccine or treatment. Our preliminary data suggest a previously unsuspected mechanism of human defense against T. cruzi and other parasites - killer lymphocytes deploy their death-inducing enzymes to directly kill intracellular parasites. Understanding this novel mechanism for causing parasite death should provide new insights into vital parasite pathways that could be new targets for drug development.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI116577-03
Application #
9431176
Study Section
Immunity and Host Defense (IHD)
Program Officer
Wali, Tonu M
Project Start
2016-03-01
Project End
2021-02-28
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
3
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Boston Children's Hospital
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Ferreira, Camila Pontes; Cariste, Leonardo Moro; Santos VirgĂ­lio, Fernando Dos et al. (2017) LFA-1 Mediates Cytotoxicity and Tissue Migration of Specific CD8+ T Cells after Heterologous Prime-Boost Vaccination against Trypanosoma cruzi Infection. Front Immunol 8:1291